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Abstract: In vivo exploration of activated microglia in neurodegenerative diseases is achievable
by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting
the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made
over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of
microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson’s
disease, Huntington’s disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in
psychiatric disorders. The extent and upregulation of TSPO as a molecular biomarker of activated
microglia in the human brain is now widely documented in these pathologies, but its significance,
and especially its protective or deleterious action regarding the disease’s stage, remains under
debate. Thus, we exposed new and plausible suggestions to enhance the contribution of TSPO PET
imaging for biomedical research by exploring microglia’s role and interactions with other cells in
brain parenchyma. Multiplex approaches, associating TSPO PET radiopharmaceuticals with other
biomarkers (PET imaging of cellular metabolism, neurotransmission or abnormal protein aggregates,
but also other imaging modalities, and peripheral cytokine levels measurement and/or metabolomics
analysis) was considered. Finally, the actual clinical impact of TSPO PET imaging as a routine
biomarker of neuroinflammation was put into perspective regarding the current development of
diagnostic and therapeutic strategies for neurodegenerative diseases.
Keywords: microglial activation; neuroinflammation; PET; radiopharmaceutical; TSPO;
neurodegenerative diseases; psychiatric disorders
1. Microglia
Microglial cells are the resident macrophages of the central nervous system (CNS) that play
different roles in both physiological and pathological conditions, by maintaining brain parenchyma
integrity and involving in a wide range of neurodegenerative diseases. Microglia represent
approximately 5–15% of all cells in the human brain [1,2]. The brain homeostasis is achieved
in part though the ability of microglia to regulate inflammation, such as cytotoxicity, repair and
regeneration [3]. In parallel to their well-known immune-modulatory functions, microglia are highly
dynamic cells which contribute to the synaptic remodelling/plasticity as well as synaptogenesis,
synaptic transmission and pruning [4].
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Several cellular actors including neurons, astrocytes, T-cells and the blood brain barrier (BBB)
modulate microglial function and form a very dynamic network [5]. In particular, microglia have been
proposed to act as sensors, effectors and injury recipients of the brain homeostasis breakdown [6].
In fact, upon injury, various afferents stimuli (e.g., soluble factors, cellular interactions [7,8]) induced
morphological (i.e., amoeboid, rod, multi-nucleated, epithelioid or dystrophic state) and functional
changes of microglia, known as microglial “activation” [6,9].
In front of homeostatic disturbances (e.g., vascular or tissue damage), microglial cells shift
from sensing activity to a reactive state. Originally based on peripheral monocytes/macrophages,
the reactive phenotype of microglial cells is dichotomized into “classical activation” or M1,
pro-inflammatory and “alternative activation” or M2, anti-inflammatory reactions. According to
this concept, microglia phenotypes are defined by triggering responses to cytokines and microbial
agents. In fact, interferon-γ from T helper cell type 1 (Th1) causes M1 activation, a response usually
associated with the struggle against intracellular pathogens. In M1 state, macrophages release
pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α or ROS/RNS. On the other hand, the secretion
of IL-4 or IL-13 from Th2 promotes M2a polarization and supports tissue repair/regeneration. M2b
cells are induced by the immune complex, secrete IL-10 and regulate the immune response [10]. When
macrophages release TGF-β or IL-10 (M2c reaction), anti-inflammatory effects are observed [7,11].
Microglia polarization/action is a process highly context-dependent [12] (nature of activating stimulus;
e.g., PAMPS and/or DAMPS) which is integrated in a time-dependent fashion (acute versus chronic
injury) [6].
2. TSPO as a Target of Activated Microglia PET Imaging
2.1. TSPO
First described as a peripheral benzodiazepine receptor (PBR), the translocator protein-18
kDa (TSPO) has been fortuitously identified by Braestrup et al., using rat kidneys as a control
tissue during central benzodiazepine receptor (CBR) binding studies using [3H]-diazepam. This
secondary binding site for diazepam, which is distinct in its structure from the CBR, was shown to be
abundantly distributed in peripheral tissues [13]. It has been renamed as 18-kDa translocator protein
(TSPO) to better reflect the cellular functions and tissue distribution of this protein [14]. TSPO is a
highly hydrophobic five transmembrane domain protein mainly situated in the outer mitochondrial
membrane. TSPO is widely distributed in most peripheral organs including kidneys, nasal epithelium,
adrenal glands, lungs and heart, whilst the highest concentrations are in the steroid producing tissues;
is also minimally expressed in resting microglial cells in the healthy brain [15]. Although modestly
expressed in healthy brain parenchyma, TSPO is substantially upregulated predominantly in microglia
cells in a number of neurodegenerative and neuroinflammatory diseases during the microglia activation
process [16]. In addition to activated microglia, Lavisse et al. showed that reactive astrocytes could
also overexpress TSPO using a model of selective astrocyte activation in the rat striatum [17]. Likewise,
after brain injury induced by focal cerebral ischemia, both microglia and astrocytes have been found
to overexpress TSPO [18], with a dissimilar distribution within the infarcted lesion. Thus, astrocytes
were mainly observed in the rim surrounding the lesion core, whereas microglia were abundant in the
core of infarction [19]. Furthermore, cells of the mononuclear phagocyte lineage, such as peripheral
macrophages, also express the TSPO and, in the case of a disrupted BBB, also infiltrate the damaged
CNS due to the vascular permeability increased by neuroinflammation [20].
TSPO is thought to be involved in a wide array of vital cellular functions including porphyrin
transport and heme synthesis, regulation of cell proliferation, steroid biosynthesis and programmed
cell death [21]. TSPO’s functions in metabolic homeostasis remain unclear, especially in the
supra-physiologic stimulation of microglia. Most studies point out that high TSPO expression
attenuates ROS generation [22,23]. Gatliff and Campanella [24] recently specify to what extent TSPO
drives the mitochondrial quality control. Indeed, more than TSPO (over)expression, it seems to be
the expression ratio of TSPO to VDAC1 (voltage-dependent anion channel 1) that regulates ROS
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production. Subsequently, this ROS generation leads to an accumulation of defective mitochondria
due to an ineffective mitophagy PARK2-dependent mitochondriopathy [24], which is involved in
several neurodegenerative diseases such as Parkinson’s disease (PD) [25], Huntington’s disease
(HD) [26] and Alzheimer‘s disease (AD) [27]. Others authors suggest a role of TSPO in oxidative
stress by directly facilitating the breakdown of porphyrin [28]. The use of TSPO ligands in rodent
models of neuroinflammation (e.g., kainic acid excitoxicity [29] or intracerebroventricular infusion of
lipopolysaccharide (LPS) [30]) highlighted TSPO’s involvement in hippocampal gliosis and especially
in microgliosis.
The colocalization of TSPO upregulation and activated glia has been observed in human
degenerative disorders including AD, PD, multiple sclerosis (MS), (HD) [31] and amyotrophic lateral
sclerosis (ALS) [32]. As a result, this increased density of TSPO in CNS diseases has been considered to
be a relevant and an early biomarker to evaluate neuroinflammation over disease progression [33].
Positron Emission Tomography (PET) imaging of microglia has widely grown over the last
25 years, through the development of radiopharmaceuticals targeting several molecular biomarkers
of microglial activation. In this context, many biological targets of neuroinflammation for both
diagnosis and therapeutic purposes have been identified. Among them, TSPO has become the
reference molecular biomarker for microglia PET imaging. Thus, TSPO PET imaging has been used
for both improving the knowledge regarding the role of neuroinflammation in CNS diseases and to
assess the efficacy of novel anti-inflammatory therapeutic strategies. Yet, the upregulation of TSPO
PET radioligands’ binding is not discriminant between activated microglia, astrocytes and infiltrated
macrophages. Indeed, in AD, Venneti et al. [34] observed that astrocytes are not a negligible factor in
the increased TSPO PET radioligand binding. Moreover, TSPO overexpression in both astrocytes and
microglia seems to be temporally distinct depending on the stage of disease and the disease itself [35].
Thus, TSPO PET imaging is not selective of microglia activation, but depicts a broader multicellular
inflammatory reaction.
In this section, we summarize the progress being made in both the involvement of microglia in
various neurologic conditions and the understanding of microglial activation in CNS disorders thanks
to TSPO PET molecular imaging.
2.2. TSPO PET Tracers
A wide variety of endogenous compounds like diazepam, cholesterol or porphyrin interacts
with TSPO at distinct binding sites. Because of the availability of high affinity and selective ligands,
which can be labeled with various radioisotopes (11C, 18F), the distribution of TSPO can be visualized
with PET technique. Historically, the benzodiazepine 11C-Ro5-4864 was the first ligand able to
discriminate peripheral from central benzodiazepine receptors. Then, the most widely used TSPO
PET radiopharmaceutical, namely 11C-(R)-PK11195, an isoquinoline carboxamide developed in the
early 1980s, was the first non-benzodiazepine type compound identified to bind to TSPO with high
affinity (human Kd = 2 nM) [36]. However, 11C-(R)-PK11195 clinical usefulness is narrowed by several
major limitations, including the short half-life of carbon-11, a low brain bioavailability and a poor
signal-to-noise ratio due to high nonspecific binding [37]. To counteract these drawbacks, there has
been a great effort for the development of second generation TSPO PET radiotracers [38–40], including
phenoxyarylacetamides derivatives labeled with carbon-11 (11C-PBR28, 11C-DAA1106) or fluorine-18
(18F-FEPPA, 18F-PBR06), imidazopyridines derivatives (11C-CLINME) and pyrazolopyrimidines
derivatives (18F-DPA-714). Indeed, a single nucleotide polymorphism in the TSPO gene (rs6971)
leading to an amino-acid substitution (A147T) has shown to be the cause of binding affinity properties
variation with a huge heterogeneity in PET images and their associated quantitative data. The fact that
the second-generation radiopharmaceuticals have been found to be sensitive to this polymorphism
leads searchers to develop rs6971-insensitive radioligands. These rs6971-insensitive radioligands,
called third generation TSPO tracers, include 11C-ER176 [41] and flutriciclamide (18F-GE180) [42].
Nonetheless, the clinical relevance of these compounds remains to be confirmed [41].
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Table 1. A summary of the different generation of TSPO radiotracers from Vivash and O’Brien [43].
Chemical Class Radioligand Advantage Limitation Generation
Isoquinoline carboxamide 11C-PK11195 rs6971-insensitive
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TSPO PET tracers have been investigated in various preclinical and clinical studies and we have
now reported major advances provided by the development of new tracers (Table 1).
3. Clinical Input of TSPO PET Imaging in Neurodegenerative Diseases
3.1. Parkinson’s Disease and Related Syndromes
Parkinson’s disease (PD) is a common age-related neurodegenerative disorder that mainly affects
the motor system. Symptoms include resting tremor, asymmetrical bradykinesia and muscular
rigidity. PD results from the progressive degeneration of dopaminergic neurons, initially in the
substantia nigra, which causes a clinical parkinsonism when the loss of the striatal dopamine
reaches to 60% [44–46]. PD is neuropathologically characterized by a neuronal rarefaction in the
substantia nigra pars compacta and the presence of neuronal Lewy bodies (LB) inclusions, which
are abnormal aggregates of α-synuclein [47]. Since the discovery of activated microglia in a post
mortem study of PD brains, objectified by a large amount of HLA-DR-positive microglial cells
in the locus niger, “neuroinflammation” became one of the main culprits in the pathogenesis and
in the progression of PD [48]. Correlation analysis between TSPO tracer binding potential values
and clinical parameters show that microglial activation PET imaging should predict the symptom
severity, but only in early-stage PD patients (Table 2) [49–51]. Indeed, the nigral 11C-PK11195
accumulation was significantly positively correlated with the motor severity of the UPDRS assessment
(unified Parkinson’s disease rating scale) in drug-naïve PD patients [49]. In addition, PD patients
presented significantly increased 11C-PK11195 uptake in the basal ganglia (striatum and pallidum),
thalamus, brainstem and frontal, temporal and cortical regions [51,52]. This TSPO overexpression
in different cerebral regions supports the notion that microglial activation is not confined to
nigrostriatal dopaminergic neurons within PD pathophysiology. Moreover, identified by positive
CD68 immunoreactivity, amoeboid activated microglial cells were identified in both the striatum
and the hippocampus of PD patients, suggesting that an inflammatory response occurs to the active
α-synuclein pathology in the hippocampus area [53]. Furthermore, TSPO PET imaging shows that
the microglial shift, from a sensing to a reactive state, takes place at the early stage of PD [49,54]
and can occur even without dementia [52,55]. This was corroborated by reported data from a rat
model of PD, where the activation of microglia seems to precede dopaminergic neuronal cell loss [56].
Given the fact that a chronological spread of LB inclusions occurred in α-synucleinopathies [57],
and these α-synuclein can directly provoke microglial activation [58], we could expect to find, in
a time-dependent fashion, a widespread TSPO signal in PET imaging. Interestingly, Gerhard and
colleagues [51] reported a lack of change in levels of cortical and subcortical TSPO tracer uptake
for two years, despite the clinical deterioration of PD patients. Similarly, microglia TEP imaging
followed-up with a second generation of TSPO radioligand (11C-DPA713) also failed (in ROI—Regions
of interest—analysis) to show increased tracer binding at one year in earlier stage PD patients [55].
Therefore, microglial activation assessed by TSPO PET imaging seems to be relatively static over time
in PD, and only microglia phenotypes may change with the disease progression.
Multiple system atrophy (MSA) is another form of atypical parkinsonism in which overlapping
symptoms as well as tremor, akinesia and rigidity are associated with autonomic failure and cerebellar
dysfunction. In contrast to PD, the accumulation of α-synuclein fibrils leads to the generation of glial
cytoplasmic inclusions (GCI) which affects mostly the oligodendroglia rather than neurons [59].
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Table 2. PET imaging studies assessing TSPO tracers in parkinsonian disorders.
Disorder Population Radioligand Main Findings References
PD
10 early-stage drug-naive PD patients vs. 10 HC 11C-PK11195
Midbrain tracer BPND in PD group greater than in the healthy volunteers
No significant difference in thalamus or striatum binding Ouchi et al. (2005) [49]
- 18 PD patients with a wide range of disease
severity vs. 11 HC
- 8 PD patients with a longitudinal follow-up
(PET after 18–28 months)
11C-PK11195
- Significantly increased tracer BPND in basal ganglia, cortex and brainstem
in PD group
- Nigral and striatal levels of 11C-PK11195 binding remain unchanged
Gerhard et al. (2006) [51]
14 PD patients vs. 8 HC 11C-PK11195 PD patients showed higher putamen and midbrain tracer BPND than controls Bartels et al. (2010) [60]
6 early-stage drug-naive PD patients vs. 11 HC 11C-PK11195
PD patients showed increased putamen and substantia nigra tracer BPND than
healthy subjects Iannaccone et al. (2013) [54]
9 PD patients vs. HC 11C-PK11195
Pons tracer BPND in PD group greater than in the control group
No significant difference in thalamus, striatum or midbrain binding Kobylecki et al. (2013) [61]
8 PD patients without dementia vs. 10 HC 11C-PK11195 BPND significant increase in temporal, parietal and occipital cortical regions Edison et al. (2013) [52]
19 PD patients vs. 17 HC 18F-FEPPA No significant difference in striatal VT values between PD patients and controls Koshimori et al. (2015) [50]
- 11 PD patients without dementia vs. 12 HC
- 11 PD patients were rescanned after 1 year
11C-DPA713
- Significantly increases 11C-DPA713 BPND in brainstem, basal ganglia and
occipital, temporal plus parietal cortex in PD group
- In ROI analysis, extrastriatal 11C-DPA713 BPND remains stable
Terada et al. (2016) [55]
PD-RCT 24 PD patients: 18 with AZD3241 vs. 6 withplacebo
11C-PBR28
Compared to baseline, significantly reduced VT in nigrostriatal pathway, cortical
regions, thalamus and cerebellum after 4 and 8 weeks of treatment
No significant differences in changes of VT between the two arms
Jucaite et al. (2015) [62]
MSA 5 MSA patients vs. 6 HC 11C-PK11195
Increased tracer binding in dorsolateral prefrontal cortex, putamen, pallidum,
pons and substantia nigra Gerhard et al. (2003) [51]
MSA-RCT 8 MSA-P patients: 3 with minocycline vs. 5 inplacebo arm
11C-PK11195
Compared to baseline, tracer BPND decreased in caudate nucleus, thalamus,
midbrain and cerebellum for 2/3 treated patients after 24 weeks of minocycline
In placebo group, tracer BPND is increased in most regions after 6 months
No statistically correlation between clinical markers and radioligand BPND
Dodel et al. (2010) [63]
PSP
- 4 PSP patients vs. 7 HC
- 2 PSP patients with a longitudinal follow-up
(PET after 6–10 months)
11C-PK11195
- Basal ganglia, thalamus, midbrain, substantia nigra, pons, cerebellum and
frontal lobe tracer BPND in PSP group higher than in the healthy controls
- No significant change in 11C-PK11195 binding
Gerhard et al. (2006) [51]
MSA/PSP 7 MSA and 4 PSP patients vs. 7 HC 11C-PK11195
Increased tracer binding in putamen, thalamus, midbrain, frontal and deep
white matter Kobylecki et al. (2013) [61]
CBD
4 CBD patients vs. HC 11C-PK11195
Significantly increased tracer BPND in striatum, substantia nigra, pons and
cortical regions Gerhard et al. (2004) [64]
1 patient with 3 year-history of CBD 11C-PK11195
Marked retention of tracer in posterior putamen, thalamus; moderately in
pallidum, substantia nigra and caudal pons Henkel et al. (2004) [65]
BPND, binding potential; CBD, corticobasal degeneration; MSA, multiple system atrophy; MSA-P, multiple system atrophy Parkinson-type; HC, healthy control; PD, Parkinson’s disease;
PSP, progressive supranuclear palsy; RCT, randomized controlled trial; ROI, region of interest; VT, total distribution volume.
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In MSA patients, significantly increased 11C-PK11195 uptake has been observed in the dorsolateral
prefrontal cortex, putamen, pallidum, pons and substantia nigra, reflecting the known distribution of
microglial and neuronal lesions in MSA [66]. Additionally, TSPO is overexpressed in the white matter of
MSA and Progressive Supranuclear Palsy (PSP) patients [61]. In MSA, these results appear to echo the
findings of neuropathological studies and could reflect the demyelination process which predominantly
affects the MSA-C variant [67]. Unlike the PD scenario progression, microglial activation in a mouse
model of MSA-like neurodegeneration occurred parallel to the dopaminergic neuronal loss in the
locus niger [68]. Remarkably, the analysis of histopathological patterns of MSA brains revealed that
the amount of GCIs and the level of microglial activity is reduced especially since the tissue injury
becomes severe in white matter areas, unlike gray matter areas [69]. If we generalize this concept
of microglial (down/up)-regulation according to lesion severity in MSA, that could explain that
11C-PK11195 binding increased in the thalamus or decreased in the substantia nigra after 24 weeks of
active disease, compared to baseline [63].
Apart from α-synucleinopathies, tauopathies such as PSP and corticobasal degeneration (CBD)
belong to parkinsonian disorders. In addition to parkinsonism, the clinical features of PSP include
early falls and abnormal eye movements (vertical supranuclear gaze palsy) [70]. The hallmark of PSP
comprises the deposition of 4-repeat (4R) tau protein in neurofibrillary tangles and neuropil threads
that are found in the basal ganglia and brainstem [71].
In vivo microglia imaging showed increased 11C-PK11195 binding in basal ganglia, thalamus,
midbrain, substantia nigra, pons, cerebellum and frontal lobe in PSP patients [51]. A post mortem
study by Fernández-Botrán et al. [72] specified that the high degree of correlation between microglial
activation, tau burden and the areas of degeneration (substantia nigra and subthalamic nucleus)
previously described [73], involves a high expression level of IL-1β. Although the involvement of
microglial activation as etiology or consequence remains unclear, these results suggest that there
is an M1 reactive phenotype of microglial cells at a point of PSP progression. Similar to PD, while
PSP patients clinically declined over 6 to 10 months, there were no significant changes in TSPO PET
imaging [51].
CBD is a rare neurodegenerative tauopathy in which the hyperphosphorylated 4R tau deposits
concern neurons and glia, in both the cerebral cortex and the basal ganglia. In CBD, a recent report
supports that astrogliopathy precedes neuronal loss, which leads to clinical symptoms as well as
asymmetrical akinetic-rigidity, apraxia, disequilibrium and limb dystonia [74]. Elevated 11C-PK11195
binding in the striatum, thalamus and substantia nigra [64,65] is in consonance with neurological
injury patterns in CBD [73,75], especially tau load [74]. Besides the diagnostic interest of PET,
molecular imaging has also been used as a tool to evaluate treatment efficacy in neurodegenerative
disorders [60,62,63].
3.2. Huntington’s Disease
Huntington’s disease (HD) is an autosomal dominant inherited trinucleotide (CAG) repeat
neurodegenerative disorder in which the age at onset is inversely correlated with the size of the
polyglutamine repeat expansion [76]. This feature allows for the dichotomization of HD patients
into premanifest HD, i.e., gene carriers are clinically asymptomatic, and manifest HD, that is to
say, after motor onset of the disease [77]. This mutation in the exon 1 of the gene encoding the
Huntingtin protein (HTT) leads to a mutant HTT (mHTT) which is expressed by peripheral monocytes
of premanifest HD patients [78], and induces both a loss of function (e.g., regulating intracellular
transport, controlling apoptosis pathway) and a gain of toxic functions (e.g., abnormal protein-protein
interaction, promoting pro-inflammatory cytokines) [79,80]. HD is neuropathologically characterized
by the formation of intranuclear inclusions of mHTT [81] resulting in striatal, cortical and hypothalamic
atrophy [82,83] which are associated with an accumulation of reactive microglia in these same
regions [31,84]. In line with these findings, in vivo microglia PET imaging showed an overexpression of
TSPO in the striatum [84–88] ,cortical regions [85,87–89] and hypothalamus [87,88] (Table 3). According
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to lesion topology, which even depends on the stage of HD, symptoms include motor troubles (chorea,
parkinsonism), cognitive decline (slowed mentation, impaired strategy) and psychiatric disorders
(mood, irritability, apathy, depression) [77,90]. To such an extent, microglial activation seems to begin
in cognitive regions, especially in associative striatum and correlated with cognitive dysfunction [88].
Moreover, striatal 11C-PK11195 binding is strongly correlated with the five-year probability of disease
onset in asymptomatic HD gene carriers [86,88]. Furthermore, in manifest HD patients, the correlation
between striatal TSPO tracer binding and the severity of motor symptoms (evaluated by the unified
Huntington’s disease rating scale) [85,88] could echo the ex vivo relationship found between neuronal
loss and density of reactive microglia [84]. Although HD is a monogenic disease, recent studies
revealed that different genes, distinct from the HD locus itself, could change disease manifestation
and progression [91]. We hypothesize that these genetics and thus clinical features could explain the
difference in microglial activation, objectified by ventral striatum TSPO tracer binding variability in
premanifest HD patients [88,89].
Table 3. PET imaging studies assessing TSPO tracers in Huntington’s disease.
Population Radioligand Main Findings References
11 manifest HD
patients vs. 10 HC
11C-PK11195
Significantly increased tracer BPND in striatum, pallidum,
frontal and parietal cortical areas in HD group
Significant correlation between striatal 11C-PK11195 BPND and
motor symptoms severity
Pavese et al.
(2006) [85]
11 premanifest HD
patients vs. 10 HC
11C-PK11195
Striatal and cortical (frontal, parietal, temporal, occipital) tracer
BPND greater in HD patients than in healthy subjects
Tai et al.
(2007) [86]
10 premanifest HD
patients, 9 manifest
HD patients and
10 HC
11C-PK11195
Tracer uptake is significantly higher in hypothalamus and
striatum in premanifest and manifest HD than in
healthy volunteers
No significant difference in binding between premanifest and
manifest HD
No significant relationship between motor symptoms and
11C-PK11195 BPND in hypothalamus
Politis et al.
(2008) [87]
8 premanifest HD
patients, 8 manifest
HD patients and
16 HC
11C-PK11195
In premanifest patients, significantly increased BPND
radioligand in cognitive regions compared to normal controls
Same results for symptomatic HD, with additional increases in
pallidum, anterior prefrontal cortex and limbic striatum
Politis et al.
(2011) [88]
12 premanifest HD
patients vs. 12 HC
11C-PK11195
Significant increases in BPND radioligand in striatum, pallidum,
thalamus and precentral gyrus in premanifest HD patients
versus healthy controls
Politis et al.
(2015) [89]
BPND, binding potential; HD, Huntington’s disease; HC, healthy control.
3.3. Dementia
Alzheimer’s disease (AD) is the most prevalent neurodegenerative cause of dementia and is
characterized by amnesic memory impairment, language deteriorate and behavioral changes due to
cognitive decline [92]. The neuropathological hallmarks of AD include extracellular peptide amyloid
β (Aβ) forming neuritic plaques and neurofibrillary tangles (NFTs) of intraneuronal deposits of
hyperphosphorylated/misfolded tau proteins. Each of these lesions has a characteristic distribution
during the evolution of AD and has a more or less strong clinicopathological correlation. A transcellular
propagation of abnormal tau proteins [93] and Aβ [94] occurred in AD. Regarding the neurofibrillary
degeneration, it starts in the entorhinal cortex and then spreads to synaptically connected brain
areas such as the hippocampus/limbic system, and finally affects the frontal and parietal lobes (i.e.,
associative isocortex) [95]. The amount and the topography of these NFTs match with the neuronal loss
and correlate with the severity and the duration of dementia as well as lesions topology (e.g., neocortex,
limbic system) is in consonance with the clinical features of AD (e.g., cognitive impairment) [96].
Moreover, tau hyperphosphorylation seems to be promoted by a pro-inflammatory environment
(e.g., IL-6 release [97]) and may support microglial activation [98], highlighting the vicious circle of
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tauopathy’s process in AD (for review, see Calsolaro et al., 2016 [99]). Microglia PET imaging supported
these experimental results. Indeed, microglia PET imaging revealed greater radioligand uptake in AD
patients than in healthy controls in the same regions which are sequentially affected by neurofibrillary
degeneration: entorhinal cortex [100–102], hippocampus [101,103,104], frontal [103–106] and parietal
cortex [100,101,103–110] (Table 4). Longitudinal studies exhibited an increase in cortical-activated
microglia during the course of AD [101,103,110]. Similarly, cross-sectional post mortem studies using
the temporal neocortex of 40 AD subjects with a symptom duration ranging from 4 to 20 years showed
a significant positive association between CDC68+ microglia and symptom duration [101]. Comparison
in TSPO density between mild cognitive impairment due to AD (MCI) and AD dementia yielded
ambiguous results: significant difference was found between the two groups [101,102,109] or was
absent [110–112] according to different studies. MCI represents a diagnostic entity for the transition
between normal aging and AD dementia [113]. Analogous to Aβ and tau that has already accumulated
in the brain of MCI patients [114], PET imaging showed that microglial activation occurred before the
onset of clinical symptoms of dementia [108,110,115]. These results are consistent with the presence
of neuroinflammatory biomarkers in the cerebrospinal fluid of pre-symptomatic AD subjects [116].
Nevertheless, some studies provided contradictory results [109,111,112].
Unlike NFTs, amyloid plaques deposition showed a lesser stereotypical spatiotemporal pattern
of progression; they accumulate mainly in the isocortex, and the amyloid burden does not correlate
with the severity or the duration of dementia [117,118]. Supported by various biomarker-autopsy
correlation studies, Jack et al. [119] proposed that AD biomarker curves assume a sigmoidal shape
as a function of time, involving a threshold effect and a late deceleration of tau and Aβ loads. With
current data on microglial activation, it seems difficult to give a similar trend to the progression of
neuroinflammation in AD dementia. However, microglial activation states obviously play a significant
role in aging and age-related disease, especially in AD. Aβ (both, soluble [120] and fibrillary [121])
can bind to several Toll-like receptors (TLR) and co-receptors expressed on microglia, leading to its
activation [122] and promoting the formation of clusters of activated microglia surrounding amyloid
plaques in AD brains [123]. In line with these ex vivo findings, TSPO PET imaging showed higher
microglial activation in various cortical regions known to be the seat of Aβ deposits [124] (e.g.,
prefrontal [104,107,108], temporal [100–102,104–109,125], occipital [101,104,105,107,108,125],
precuneus [101,109,110], cingulum [100,104,110]) in AD dementia patients, compared to
healthy subjects. This Aβ-induced inflammatory environment [126], combined with effect of
immunosenescence on microglia [127,128], lead to a situation in which microglia that initially exhibited
a neuroprotective M2 phenotype at the beginning of AD [129], become confined to a classical activated
state (i.e., M1) with strongly reduced Aβ-clearing capabilities in the advanced stage of AD [7].
Correlation analysis between TSPO tracer binding and AD severity provided heterogeneous
findings. In most studies, in parallel to cognitive deterioration, objectified by a decreased MMSE
score [105,106,125] or increased CDR-SB [101,109], TSPO expression density in cortical regions was
linearly raised. To the same extent, Kreisl et al. [101] exhibited that early onset AD (EOAD) patients
presented significantly higher 11C-PBR28 than later onset AD (LOAD) patients, both at baseline and
follow-up. This overexpression of activated microglia in more active AD (i.e., early onset) may confer
on it the status of a deleterious process. Other studies found no link [105,108,109,113]. Conversely, one
of the surprising results of the study of Hamelin et al. [110] is that MMSE scores correlate positively
with TSPO tracer binding. Moreover, the radioligand (18F-DPA-714) GCI was greater in slow decliners
than in fast decliners, suggesting an early neuroprotective effect of microglial activation in AD.
In light of such antipodic findings, we cannot exclude the fact that TSPO PET imaging has limited
abilities to robustly reflect microglial activation in AD. In fact, Banati et al. [33] suggested that the
overexpression of TSPO in activated microglia may be related to structural changes in mitochondria
due to morphological changes in microglial cells. On the basis of that postulate, we hypothesize that
the profound morphological deterioration of microglial cells which occurred in AD [128] could be a
source of signal variability in TSPO PET imaging.
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Table 4. PET imaging studies assessing TSPO tracers in dementias.
Disorder Population Radioligand Main Findings References
FTLD 5 FTLD vs. 8 HC 11C-PK11195
Significantly increased radioligand binding in cortical frontal, medial temporal and
subcortical areas in FTLD group Cagnin et al. (2004) [130]
FTDP-17 3 presymptomatic MAPTgene carriers vs. 4 HC
11C-DAA1106
11C-DAA1106 BPND greater in the medial frontal, occipital and in the posterior cingulate
cortex of pre-symptomatic gene carriers than in healthy volunteers
Miyoshi et al. (2010) [131]
DLB 11 early-stage drug-naive DLBpatients vs. 11 HC
11C-PK11195
DLB patients showed increased subcortical (basal ganglia, substantia nigra) and cortical
(cerebellum) tracer BPND
Iannaccone et al. (2013) [54]
PDD 11 PDD patients vs. 10 HC 11C-PK11195 BPND significant increase in frontal, temporal, parietal and occipital cortical regions Edison et al. (2013) [52]
PDD/AD
10 AD, 10 MCI, 11 PDD
patients and 16 HC
11C-PK11195
Significantly increased tracer BPND in cortical and subcortical regions of AD, PDD and MCI
patients compared with controls
Significant negative correlation between MMSE and 11C-PK11195 BPND in temporoparietal,
occipital and frontal cortex of AD and PDD patients
Fan et al. (2015) [125]
9 PDD, 8 AD and 8 HC 11C-PK11195
Tracer was significantly increased in cortical regions of AD and PDD patients, compared
to controls
Femminella et al.
(2016) [132]
AD
8 AD patients vs. 15 HC 11C-PK11195
Significantly increased radioligand binding in the entorhinal, temporoparietal and
cingulate cortex
1 patient with isolated memory impairment but without dementia exhibited an increase of
11C-PK11195 binding in the fusiform gyri, inferior temporal gyri and parahippocampus
Cagnin et al. (2001) [100]
13 AD patients vs. 10 HC 11C-PK11195
Significantly increased tracer BPND in the cortical and subcortical regions in AD patients
Tracer binding in gray matter and cortical regions negatively correlated with MMSE scores Edison et al. (2008) [105]
10 AD patients vs. 10 HC 11C-DAA1106
Significantly increased 11C-DAA1106 BPND in the cerebellum, cortical regions (prefrontal,
lateral temporal, parietal and occipital cortex) and striatum in AD patients, compared to
age-matched control subjects
Yasuno et al. (2008) [107]
13 MCI patients vs. 10 HC 11C-PK11195
5/13 patients showed higher cortical tracer BPND than in controls
Only frontal cortex radioligand uptake was significantly raised in MCI patients Okello et al. (2009) [115]
6 mild-moderate AD patients,
6 MCI patients and 5 HC
11C-PK11195 TSPO PET images showed no significant difference between the three groups Wiley et al. (2009) [111]
11 drug-naïve AD patients vs.
10 HC
11C-PK11195
Significantly increased 11C-PK11195 BPND in the medial frontal, parietal and left temporal
cortex in the AD group
Significant inverse correlation between MMSE score and 11C-PK11195 BPND in anterior
cingulate cortex, precuneus and hippocampus
Yokokura et al. (2011) [106]
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Table 4. Cont.
Disorder Population Radioligand Main Findings References
AD
6 AD patients vs. 12 HC 11C-vinpocetine
No significant difference between AD patients and age-matched control subjects in SUV of
all brain regions Gulyas et al. (2011) [133]
10 AD, 7 MCI patients and
10 HC
11C-DAA1106
Mean BP values of MCI and AD patients higher than those of controls in prefrontal,
parietal, temporal, occipital and cingulate cortex, striatum, cerebellum and thalamus
No difference in binding was found between AD and MCI patients
Yasuno et al. (2012) [108]
19 AD, 10 MCI patients and
13 HC
11C-PBR28
Significantly increased tracer binding in inferior parietal lobule, middle plus inferior
temporal cortex and precuneus in AD patients, compared to MCI patients and HC
EOAD patients had greater binding than LOAD
Kreisl et al. (2013) [109]
19 probable AD, 10 MCI
patients and 21 HC
11C-PK11195
ROI based analyses showed no differences between diagnostic groups, with large overlap
between subject groups
Schuitemaker et al.
(2013) [112]
9 AD patients vs. 7 HC 18F-FEDAA1106 No significant change in 18F-FEDAA1106 binding between AD and HC Varrone et al. (2013) [134]
- 8 AD patients vs. 8 HC
- AD patients were
followed-up for
16 months
11C-PK11195
- AD patients showed a mean increase of 30% radioligand BPND in frontal, temporal,
parietal, occipital cortical regions, hippocampus and striatum
- In parallel to cognitive deterioration, microglial activation was increased
longitudinally in 6/8 AD patients
Fan et al. (2015) [103]
25 AD patients, 11 MCI and
21 HC
11C-PBR28
AD patients showed greater radioligand VT/fP values than MCI patients and HC in
combined middle, inferior temporal and entorhinal cortices Lyoo et al. (2015) [102]
10 AD patients vs. 7 HC 18F-FEMPA
Significantly higher radioligand VT in the medial temporal cortex in AD patients than
in controls Varrone et al. (2015) [135]
18 AD patients in moderate
stage vs. 21 HC
18F-FEPPA
Compared to HC, AD patients showed a significant increase in 18F-FEPPA binding in both,
gray matter (hippocampus, temporal, prefrontal, parietal and occipital cortex) and white
matter (cingulum bundle, posterior limb of the internal capsule)
No statistical correlation between radioligand VT in white or gray matter and AD severity
Suridjan et al. (2015) [104]
10 AD patients vs. 6 HC 18F-DPA-714
No significant difference in tracer BPND and VT in whole brain gray matter between AD
patients and HC Golla et al. (2015) [136]
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Table 4. Cont.
Disorder Population Radioligand Main Findings References
AD
- 14 AD patients vs. 8 HC
- Follow-up of 2.5 years in
AD patients
11C-PBR28
- Tracer binding (SUVr) significantly greater among patients than controls in inferior
parietal lobule, precuneus, occipital cortex, hippocampus, entorhinal cortex and
combined middle and inferior temporal cortex
EOAD patients showed significantly higher TSPO radioligand binding than LOAD patients
in several cortical regions (e.g., prefrontal and occipital cortex)
- TSPO binding in temporoparietal areas increased from 3.9% to 6.3% per annum in
patients, compared with only −0.5–1% per annum in controls
Kreisl et al. (2016) [101]
- 58 AD patients (34 MCI
and 24 dementia) vs.
32 controls (24 HC and
8 amyloidosis-controls)
- 30 AD patients were
followed-up over
2 years
18F-DPA-714
- In MAB + HAB group, tracer-GCI significantly higher in amyloidosis controls than in
HC, especially in the cingulum and the precuneus
Compared to controls, significantly increased tracer binding in temporal and parietal cortex
in AD groups, even at the prodromal stage
Significant positive correlation between the DPA-714-GCI and MMSE scores
- GCI-DPA-714 SUVr greater in the slow decliners than in the fast decliners group
Hamelin et al. (2016) [110]
AD, Alzheimer’s disease; BPND, non-displaceable binding potential; CDR-SB, clinical dementia rating scale-sum of boxes; DLB, dementia with Lewy bodies; EOAD, early-onset AD;
FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17; FTLD, frontotemporal lobar degeneration; fP, plasma-free fraction of radioligand; GCI, global cortical
index; HAB, TSPO high affinity binders; HC, healthy control; LOAD, late-onset AD; MAB, TSPO mixed affinity binders, MCI, mild cognitive impairment; MMSE, mini-mental state
examination; ROI, region of interest, SUVr, standard uptake value ratio; PPD, Parkinson’s disease dementia; VT, total distribution volume.
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Frontotemporal lobar degeneration (FTLD) is a clinically, pathologically and genetically
heterogeneous syndrome characterized by progressive clinical features such as behavioral and
personality changes, cognitive decline and parkinsonism [137]. These symptoms result from
progressive neurodegeneration and, ultimately, focal atrophy of the frontal and temporal cortex
in which inclusions of hyperphosphorylated tau protein in neurons and glial cells (FTLD-tau)
and inclusions of TDP-43 (FTLD-TDP) compose the two main histopathological hallmarks of this
disease [138]. FTLD has a strong genetic component; mutations causing FTLD include MAPT
(microtubule-associated protein tau) and progranulin [139]. Interestingly, proganulin is expressed by
activated microglia [140] and polarizes microglial cells into M2 anti-inflammatory phenotypes [130],
suggesting that microglia polarization deficiency could play a role in FTLD. Indeed, Cagnin et al. [133]
demonstrated an enhanced uptake of tracer (11C-PK11195) in the typically affected frontotemporal
regions. Two MAPT pre-symptomatic gene carriers exhibited microglial activation in either, posterior
cingulate cortex, region which sends projection to the superior temporal sulcus, or in the medial frontal
cortex [131]. Elevated putaminal uptake of TSPO tracer in frontotemporal dementia patients [130] is
consistent with the neuropathological (involvement of the basal ganglia [141]) and clinical features
(parkinsonism [142]) of FTLD.
3.4. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a rare adult-onset neurodegenerative disorder in which
upper and lower motor neurons degenerate leading to progressive muscle paralysis then respiratory
failure with a fatal outcome, typically within 2–4 years from onset [143]. This motoneuropathy that
occurred from 5% to 20% in a positive family history of ALS, fronto-temporal demence (FTD) or both,
results in fasciculation, cramps, muscle atrophy associated with hyperreflexia and spasticity [144,145].
Central inflammation has been proposed to play a role in the motor neuron death process in ALS [146].
TSPO PET imaging supported this assumption. Indeed, ALS patients presented significantly greater
TSPO tracer binding in motor cortex than healthy volunteers [32,147,148]. Moreover, “microgliopathy”,
assessed by CD68- and Iba1-reactive microglial cells, correlated with the disease progression and
is linked to the severity of upper motor neuron deficits in the corticospinal tract of ALS patient
autopsies [149]. These ex vivo findings were clinically sustained by PET studies, where TSPO
expression density was correlated with motor symptoms severity, assessed by the UMND (Upper
Motor Neuron Disorders) score [32,147] (Table 5). Interestingly, the one study that described an
elevated TSPO radioligand uptake (11C-PBR28) in the brainstem of bulbar-onset ALS patients was also
the one in which a statistical correlation was found between SUVr values and ALSFRS-R (revised ALS
functional rating scale) [147]. Given the fact that this functional scale is more accurate to evidence
lower motor neuron involvement [32], this association is probably due to the fact that microglial
activation in the brainstem could reflect inflammation around the lower motor neurons of the cranial
nerves [147]. The murine model of ALS, in which microglial cells overexpressed mutant-superoxide
dismutase (mSOD1), the main cause of non-sporadic ALS, point out the pathogenic role of microglia in
ALS; mutant protein may be more involved in disease progression than in its initiation [150]. Inversely,
activated microglia in the temporal region could be involved in the early stage of ALS [148], and
then progressively decrease. Indeed, this cerebral area was not affected in ALS patients with a more
advanced stage [32,147]. Like AD dementia, a switch from the classically activated M1 phenotype to the
alternatively activated M2 microglial state takes place during the progression of ALS disease [151,152].
Int. J. Mol. Sci. 2017, 18, 785 14 of 37
Table 5. PET imaging studies assessing TSPO tracers in amyotrophic lateral sclerosis.
Population Radioligand Main Findings References
10 ALS patients without
dementia (2 bulbar-onset
and 8 limb-onset) – mean
disease duration =
25 months
11C-PK11195
The difference in tracer binding between ALS and
controls reached significance in motor cortex, pons,
frontal lobe region and thalamus
Statistical correlation between BPND values and
UMNB scores for both motor cortex and thalamus
was found
No clear difference in the binding of 11C-PK11195
between ALS patients with bulbar- or limb-onset
No correlation between tracer uptake with either
disease duration or ALSFRS-R was seen
Turner et al.
(2004) [32]
10 riluzole-naive ALS
patients without
dementia (6 bulbar-onset
and 4 limb-onset) vs.
8 HC
– mean disease duration
= 12 months
18F-DPA-714
Primary motor, supplementary motor and temporal
regions 18F-DPA-714 DVr values were greater in ALS
patients than in age-matched healthy volunteers
No significant difference in occipital and frontal
cortex, thalamus, cerebellum or pons was found
between the two groups
No correlation between DVr values and disease
duration or ALSFRS-R
Corcia et al.
(2012) [148]
10 ALS patients
(3 bulbar-onset and
7 limb-onset) vs. 10 HC
– mean disease duration
= 22 months
11C-PBR28
Significantly increased tracer binding in the primary
motor cortex and upper region of the corticospinal
tract in ALS patients
Tracer SUVr of the right precentral gyrus was
positively correlated with UMNB scores and
negatively correlated with ALSFRS-R
No statistical correlation was found between
radioligand uptake in the precentral gyrus and
disease duration
ALS patients with limb-onset showed significantly
higher SUVr than patients with bulbar onset in the
precentral gyrus
Zürcher et al.
(2015) [147]
ALS, amyotrophic lateral sclerosis; ALSFRS-R, amyotrophic lateral sclerosis functional rating scale revised; BPND,
binding potential; DVr, distribution volume ratio; HC, healthy control, SUVr, standard uptake value ratio; UMNB,
upper motor neuron burden scale.
3.5. Psychiatric Disorders
Bipolar disorder (BD) is a chronic mood trouble in which episodes of elevated mood and manic
state are typically alternated with major depressive access, interspersed by euthymic periods [153].
Although the pathophysiology of this severe mental illness remains to be elucidated, a large body of
literature suggests that several pathophysiological processes may sequentially and/or concurrently
occur in BD, as well as corticolimbic control circuits deterioration, monoaminergic neurotransmission
imbalance or microglia homeostasis disruption (for review, see Sigitova et al., 2016 [154]). Among
these, hippocampal neuroinflammation, assessed by enhanced 11C-PK11195 binding compared to
healthy subjects [155], could echo the change in the cytokines pattern’s profile (TNF, IL-1, IL-2 and
IL-6) of BD-I patients [156] (Table 6).
Major depressive disorder (MDD) is a highly prevalent condition, affecting nearly 4% of the adult
population [157], which could complicate neurodegenerative disorders (e.g., MS [158], PD [159]) or be
isolated, without comorbidities. Although this depressive disorder mainly concerns mood disturbance,
clinical features include a large range of symptoms as cognitive deficits, vegetative impairment (e.g.,
loss of appetite, sleeping difficulties) or behavioral deterioration (e.g., anhedonia, suicidal ideation).
Several data, such as the association between central inflammation and depression-like symptoms
in rodents [160], abnormalities in peripheral cytokines of depressed patients [161], or association
between interferon alpha in the context of hepatitis C and depressive symptoms [162], have led some
investigators to propose a microglial dysregulation theory for MDD etiology [163]. Nevertheless, post
mortem studies have questioned this assumption. Indeed, no evidence of microglial activation was
found in the brain of MDD patients [164–166]. In line with these results, microglia PET imaging did not
Int. J. Mol. Sci. 2017, 18, 785 15 of 37
reveal any statistical difference in 11C-PBR28 binding between healthy volunteers and patients with
mild to moderate depression [167]. However, Setiawan and colleagues [168] recently found increased
microglial activity (18F-FEPPA, VT, total distribution volume) in the anterior cingulate cortex of MDD
patients, the region known to be implicated in the modulation of emotional behavior [169]. Moreover,
this PET imaging result was correlated with the MDE (major depressive episode) severity, objectified
by a 17-item Hamilton depression rating scale (HDRS) score [168].
Table 6. PET imaging studies assessing TSPO tracers in psychiatric disorders.
Disorder Population Radioligand Main Findings References
BD 14 patients withBD-I vs. 11 HC
11C-PK11195
No significant difference in the whole-brain gray matter BP in
patients with bipolar I disorder versus healthy subjects
Significantly increased tracer binding in hippocampus of BD-I
patients, compared to normal controls
Haarman et al.
(2014, 2016)
[155,170]
MDE
10 patients with
mild to
moderate
depression vs.
10 HC
11C-PBR28
No statistically significant difference in 11C-PBR28 VT
between individuals with depression and healthy volunteers
7/10 patients exhibited lower tracer VT in cortical regions
(frontal, temporal, parietal and occipital), striatum, thalamus
and cerebellum than normal controls
Hannestad et al.
(2013) [167]
20 MDE
drug-free
patients vs.
20 HC
18F-FEPPA
In MDE patients, significant elevation of TSPO VT in the
prefrontal cortex, anterior cingulate cortex and insula, of 26%,
32% and 33%, respectively, compared to normal controls
Anterior cingulate cortex TSPO VT correlated with total
17-item HDRS score
Setiawan et al.
(2015) [168]
SCZ
10 patients with
recent-onset
SCZ vs. 10 HC
11C-PK11195
Significantly greater total gray matter tracer BP in SCZ
patients than in healthy volunteers
No statistical correlation between total gray matter
11C-PK11195 BP and PANSS
Van Berckel et al.
(2008) [171]
7 SCZ patients
vs. 8 HC
11C-PK11195
Significantly higher radioligand BP was observed in the
hippocampus of SCZ patients than in HC
Although the difference did not reach a significance level, the
whole-brain gray matter and white matter were, respectively,
30% higher and 20% greater in SCZ patients than in HC
Doorduin et al.
(2009) [172]
14 SCZ patients
vs. 14 HC
11C-DAA1106
No clear difference in either regional or total cortical
radioligand BPND values between the two groups
Takano et al. (2010)
[173]
16 SCZ patients
vs. 27 HC
18F-FEPPA
No significant effect of clinical group (SCZ vs. HC) detected
on tracer VT in hippocampus, medial prefrontal cortex,
dorsolateral prefrontal cortex, temporal cortex and striatum or
in white matter tracts
None of the disease parameters (PANSS, AES and RBANS)
statistically correlated with regional radioligand VT
Kenk et al. (2015)
[174]
14 UHRP
subjects
(APT-naive),
14 SCZ patients
and 28 HC
11C-PBR28
Significantly increased tracer DVr in total gray matter and
frontal and temporal lobes in UHRP subjects and SCZ
patients, compared to age-matched controls
No statistical difference in tracer binding values between
UHRP and SCZ patients
In UHRP subjects, statistical positive correlation was found
between CAARMS and 11C-PBR28 DVr in total gray matter
Bloomfield et al.
(2016) [175]
12 recent onset
SCZ patients vs.
14 HC
11C-DPA713 Significantly increased
11C-DPA713 VT in amygdala and
cingulate cortex in SCZ patients compared healthy volunteers
Coughlin et al.
(2016) [176]
12 recent onset
SCZ patients vs.
14 HC
11C-DPA713
Relative to HC, there was a strong trend towards reduce
11C-DPA713 VT in the middle frontal gyrus of patients with
recent onset SCZ
Notter et al. (2017)
[177]
AES, Apathy Evaluation Scale; APT, antipsychotic therapy; BD, bipolar disorder; BP, binding potential; BPND,
binding potential; CAARMS, comprehensive assessment of the at-risk mental states; CDS, calgary depression scale;
DVr, distribution volume ratio; IDC-C30, inventory of depressive symptoms—clinician version; HDRS, Hamilton
depression rating scale; HC, healthy control; MDE, major depressive episodes; PANSS, positive and negative
syndrome scale; RBANS, repeatable battery for the assessment of neuropsychological status; SCZ, schizophrenia;
UHRP, ultra-high risk of psychosis; VT, total distribution volume.
Apart from epidemiological [178] and genetic [179] evidences of overlap between BD and
schizophrenia (SCZ), molecular imaging of microglia of these psychiatric disorders also share some
similarities, especially hippocampal TSPO overexpression compared to normal controls [155,172]. SCZ
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is a chronic early adult-onset psychiatric disorder in which symptoms are typically divided into positive
(e.g., hallucinations), negative (e.g., affective flattening, alogia) and cognitive (e.g., concentration and
memory impairment) [180]. Multiple lines of evidence from immunohistochemical cell counting
studies to clinical trials of a non-selective microglial inhibitor support the fact that microglia is
involved in the pathophysiology of SCZ [181]. Nevertheless, as with post mortem studies [182],
microglia PET studies provided conflicting results. Indeed, some studies revealed significantly higher
TSPO radioligand binding in SCZ patients in total gray matter [171,175], especially in the frontal and
temporal lobes [175] and the hippocampus [172] than in controls subjects. However, other studies
found no clear difference between normal controls and SCZ patients in various brain regions [173,174].
Neuroinflammation imaging in psychiatry is in an early stage, and there is much more to
investigate (for review, see Slifstein and Abi-Dargham, 2016 [183]), especially regarding TSPO imaging.
Indeed, there is evidence that the dysregulation of steroidogenesis by TSPO is associated with
psychiatric disorders. For instance, an association has been found between rs6971 polymorphism in
the TSPO gene and the diagnosis of BD [184].
3.6. Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS in which migration
of myelin-reactive T-cells into the CNS is followed by astrocyte and microglial activation,
recruitment of peripheral macrophages and oligodendrocyte destruction, resulting in focal and diffuse
demyelination [185,186]. The clinical presentation of MS as well as symptoms produced by the
episodes of neurologic dysfunction (i.e., “attacks” or “relapses”) are heterogeneous. Regarding the
symptoms of MS, tingling, weakness, vision loss, incoordination or bladder dysfunction may occur
and depend upon the site of neurologic involvement. As regards the clinical picture, the most typical
form at the onset of the disease is relapsing-remitting MS (RRMS), which is characterized by attacks
interspersing with neurologically stable periods. Over several years to decades, RRMS shifts into
secondary progressive MS; the recovery between relapses becomes partial and gradually provokes
persistent symptoms which lead to irreversible disability. Only a minority of patients (~10–20%)
experience insidious worsening without acute attacks, a clinical course known as primary progressive
MS (PPMS) [187,188]. The major substrates of the disease progression include demyelinated cortical
lesions, diffuse cortical and deep gray matter degeneration [189], which are associated with the chronic
activation of microglia [190–192]. Microglia play a central role in maintaining the central chronic
inflammation in MS [193,194], to the extent that its presence and distribution in the plaques allow
for the neuropathological classification of the nature of the white matter lesions (i.e., active versus
inactive) in secondary progressive multiple sclerosis (SPMS) [195].
Although the clinical and/or MRI discovery of dissemination of the lesions in time and space
remains the cornerstone of MS diagnostics, TSPO PET imaging could be a promising technique
to diagnose MS or to detect the conversion of RRMS to SPMS. In light of the limits of clinical
assessment (e.g., measuring EDSS, expanded disability status scale) [196] and MRI parameters [197]
to predict the progression of MS, TSPO PET studies have shown hopeful findings (Table 7). Indeed,
activated microglia in SPMS relative to RRMS are characterized by both specific and more diffuse
distribution in cortical regions [198] as well as greater TSPO radiopharmaceutical uptake, especially in
the thalamus [199,200] and deep gray matter [200]. Provided that these results will be replicated in
larger cohorts, it paves the way to early intervention in MS, thanks to TSPO PET imaging, in order to
prevent or efficiently treat SPMS. At the upstream level in the disease history, Giannetti and colleagues
demonstrated in clinically isolated syndrome (CIS), the prodromal state of MS, that patients who
developed MS at two years had higher 11C-PK11195 binding at baseline, especially in normal-appearing
white matter (NAWM) [201]. Analogous to the relationship between MCI and AD, we hypothesize
that NAWM TSPO tracer uptake of CIS subjects could allow for the establishment of an x-year
probability of disease (i.e., MS) onset. This significant increase in NAWM TSPO density, compared
to healthy volunteers, has also been found in RRMS [200] and SPMS patients [200,202]. In addition
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to detecting activated microglia in areas of the brain which appear normal in MRI, the NAWM,
TSPO PET imaging could predict the development of some gadolinium-enhancing lesions. In fact,
increased focal 11C-PBR28 binding in an area of NAWM at the time of the PET scan corresponded to a
contrast-enhancing lesion at a follow-up MRI exam one month later, as was found in two MS patients,
suggesting a role for early microglial activation in MS lesion formation [203]. Apart from the fact that
microglial activation may precede MS lesions, and that there is a greater TSPO radioligand uptake in
RRMS than in SPMS, a body of evidence gives a deleterious status of activating microglia in MS. Among
these, RRMS patients who had the greatest number of relapses (i.e., more clinically active) also had
the highest 11C-PK11195 binding potential [198,204]. Furthermore, association analysis revealed that
TSPO tracer binding levels in various brain regions correlated positively with both MS score severity
(e.g., EDSS) [198,200,205,206] and disease duration [199,203]. This set of results is in consonance with
post mortem studies in which severe cortical microglia activation and demyelination are associated
with a pejorative outcome [207–209]. Nevertheless, some microglia PET studies provide conflicting
results in terms of the association analysis in either EDSS [210,211] or disease duration [204,210].
Ratchford and colleagues [204] provided proof of the concept that microglia PET imaging with
11C-PK11195 could also be a tool to assess disease-modifying drugs for RRMS efficacity. Indeed,
radiopharmaceutical binding potential per unit volume was statistically decreased in the whole brain
after one year of glatiramer acetate. This result supported the in vitro evidence of its mechanism of
action in which an inhibition of transformation to an activated microglia form could be responsible for
therapeutic effects [212].
Table 7. PET imaging studies assessing TSPO tracers in multiple sclerosis.
Population Radioligand Main Findings References
2 RR patients 11C-PK11195 Increased
11C-PK11195 BPND in MRI-defined active MS lesions, not in
chronic lesions
Vowinckel et al.
(1997) [213]
12 MS patients
(8 RR, 1 SP and
3 PP), 8 HC
11C-PK11195
Increased global and in MRI-defined (T1/T2) active lesions radioligand
BPND in MS patients
Greater brainstem and thalamus tracer BPND in MS patients than in HC
Patient with a history of optic neuritis showed 11C-PK11195 signals in
the lateral geniculate bodies (to which the optic nerve projects)
Banati et al.
(2000) [210]
22 MS patients
(13 RR, 7 SP and
2 PP), 7 HC
11C-PK11195
No statistical difference in NAWM and GM tracer BPND was found
between MS patients and healthy volunteers
Tracer BPND significantly greater in gadolinium lesions than in NAWM
A higher 11C-PK11195 BPND was found in both situations, clinical
relapse or presence of T1-gadolinium lesions
Statistical correlation found between higher 11C-PK11195 BPND and
disease duration
Debruyne et al.
(2003) [199]
22 MS patients
(13 RR, 7 SP and
2 PP), 8 HC
11C-PK11195
NAWM tracer BPND was positively correlated with amount of
brain atrophy
Significant negative correlation between T2 lesions tracer BPND and
brain atrophy
Versijpt et al.
(2005) [214]
11 MS (mostly RR)
patients vs. 7 HC
11C-PBR28
No statistical difference in neither WM fraction or GM fraction VT
tracer between MS and healthy volunteers
Gadolinium-enhancing lesions demonstrated significantly higher
11C-PBR28 binding than contralateral NAWM
Global VT tracer showed correlation with disease duration but not with
clinical disability
Oh et al.
(2011) [203]
18 MS patients (10
RR and 8 SP), 8 HC
11C-PK11195
Proportion of abnormal high total cortical GM 11C-PK11195 BPND was
greater in SP than in RR patients
Mean total WM radioligand BPND was greater in SP than in RR patients
SP patients showed additionally increased tracer BPND in precentral,
superior parietal, lingual and anterior superior, median and inferior
temporal gyri
The 2 patients with the more active RR had the highest total cortical
GM tracer BPND
Politis et al.
(2012) [198]
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Table 7. Cont.
Population Radioligand Main Findings References
9 RR untreated
patients
Patients were
rescanned after
1 year of GA
11C-PK11195
The patient with the more active RR had the highest 11C-PK11195 BPND
on the baseline TSPO PET scan
Tracer BPND per unit volume statistically decreased in the whole brain
and especially in the following regions: supratentorial brain,
infratentorial brain, cerebral white matter, cortical gray matter,
thalamus and putamen
Ratchford et al.
(2012) [204]
9 RR in acute
relapse (6 without
treatment and
3 interferon-β
treated) vs. 5 HC
18F-FEDAA1106
Similar radioligand BPND and VT between normal controls and
MS patients
No significant difference of BPND or VT between MS patients without
treatment, MS patients with interferon-β treatment and
healthy volunteers
Takano et al.
(2013) [215]
11 RR vs. 11 HC 18F-PBR111
Increased tracer uptake in WM lesions and perilesional WM relative
to HC
Increased 18F-PBR111 VT was higher in lesions and perilesional
volumes in MS patients compared to the NAWM of the same subjects
Significant positive correlation between radioligand VT and MS
score severity
Colasanti et al.
(2014) [205]
19 MS patients
(10 RR, 8 SP and
1 PP)
11C-PK11195
Black holes tracer BPND was greater in progressive patients than in
RR patients
In RR patients, significant inverse correlation between volume and
11C-PK11195 BPND of black holes was found
Black holes tracer BPND was correlated with the EDSS in
progressive patients
Giannetti et al.
(2014) [206]
10 SP patients vs.
8 HC
11C-PK11195
Relative to controls, significantly increased tracer DVR was found in
periventricular NAWM and thalamus of SP patients
A pattern of increased TSPO density in the periplaque area
surrounding the borders of chronic plaques was observed
In active plaques with gadolinium-enhancement increased TSPO
binding was found in the core of the lesion but not in the area
surrounding them
Rissanen et al.
(2014) [202]
18 CIS patients vs.
8 HC
11C-PK11195
Compared to controls, significantly increased tracer BPND was found in
NAWM of CIS patients, while no difference was observed in GM
In CIS patients with T2 MRI lesions, NAWM tracer BPND correlated
with EDSS
CIS patients who developed MS at 2 years had higher 11C-PK11195
BPND at baseline
Giannetti et al.
(2015) [206]
5 RR patients
(4 stable and 1 drug
naive with active
RR) vs. 4 HC
11C-PBR28
VT was similar between stable MS and healthy volunteers across whole
brain and GM/WM/NAWM regional areas (frontal, parietal, temporal
and occipital)
Focal increases in tracer VT were observed at some areas corresponding
to gadolinium-enhancing lesion of active MS patients
Park et al.
(2015) [216]
9 RR patients vs.
8 HC
18F-GE180
Whole WM uptake (SUVRGM) slightly higher in RR patients than in HC
Increased tracer uptake in inactive WM lesions and a further increase in
gadolinium-enhancing lesions (Preliminary data)
Trigg et al.
(2015) [217]
11 RR patients
(6 with MDE) vs.
22 HC
18F-PBR111
18F-PBR111 DVR higher in the hippocampus of MS patients relative to
normal subjects, while no difference was observed in thalamus
Hippocampal radioligand binding was correlated to BDI scores in MS
patients and was highest in MS patients with current MDE
Colasanti et al.
(2016) [218]
23 MS patients
(16 RR and 7 SP)
11C-PBR28 No significant correlation between
11C-PBR28 DVR and EDSS in either
WM lesions, NAWN or GM
Datta et al.
(2016) [211]
27 MS patients
(12 RR and 15 SP),
14 HC
11C-PBR28
Compared to controls, significantly increased tracer DVR across the
brain was found in MS cases; the greatest increases being in cortex and
cortical lesions, thalamus, hippocampus and NAWM
Relative to the same brain regions, radioligand uptake was greater in
SPMS than in RRMS, except for cortical lesions (same TSPO levels)
In MS patients, EDSS correlated positively with increased tracer SUVR
in the NAWM, WM lesions, thalamus, hippocampus and basal ganglia
Herranz et al.
(2016) [200]
BPND, binding potential; BDI, beck depression inventory; CIS, clinically isolated syndrome; DVR, distribution
volume ratio; EDSS, expanded disability status scale; GA, glatiramer acetate; GM, gray matter; HC, healthy
control; MDE, major depressive disorder; MS, multiple sclerosis; NAGM, normal-appearing gray matter; NAWM,
normal-appearing white matter; PP, primary progressive multiple sclerosis; RR, relapse-remitting multiple sclerosis;
SP, secondary progressive multiple sclerosis; SUVR, standardized uptake value ratio; VT, total volume of distribution;
WM, white matter.
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4. Multiplex Approaches to Improve TSPO PET Imaging Significance
TSPO molecular imaging provides valuable information such as presence, intensity and
localization of the microglia activation, but this uniparametric approach might be considered as
one component of a multiplexed strategy. Indeed, TSPO imaging combined with further PET targets,
imaging techniques (e.g., MRIf), or even biology, could allow for a deeper understanding of the role
of activated microglia in neurodegenerative disorders. We organize this section into; first, unimodal
approaches, that is to say, TSPO PET imaging coupled with other PET radiopharmaceuticals; and
second, multimodal approaches associating microglia PET imaging with other modalities.
4.1. Unimodal Approaches
4.1.1. Neuroinflammation PET Imaging Targeting Molecular Biomarkers Other than TSPO
Neuroinflammation is a complex physiological response to CNS injuries involving a biochemical
molecular cascade involved in both tissue degradation and remodeling. Activation of microglia cells
that leads to cell death is often related to oxidative stress through cytokines and chemokines release,
glutamate-induced excitotoxicity, mitochondrial dysfunction or by protein aggregation. As described
above, PET studies exploring neuroinflammation in CNS disorders have mainly been focused on the
evaluation of the sole TSPO. Therefore, identifying and imaging other molecular biomarkers involved
in inflammatory cascade would be a promising approach combined with TSPO imaging.
PET imaging associating TSPO radioligands with tracers for other molecular targets involved
in microglial activation has already allowed for the assessment of temporal progression of different
biochemical mechanisms involved in neuroinflammation. Indeed, in the rodent model of cerebral
ischemia, Martín et al. have assessed in parallel the in vivo expression of both α4β2 (nicotinic
acetylcholine receptors) and TSPO in reactive glial cells using 2-18F-fluoro-A85380 and 11C-PK11195,
respectively [219]. Results have shown a progressive binding increase during the first week
after cerebral ischemia, followed by a progressive PET-binding decrease in the ischemic territory.
Likewise, differential time-dependent activation of TSPO and matrix metalloproteinases (MMPs),
protease involved in tissue degradation and remodeling has been observed by PET co-imaging with
the 18F-DPA714 and the 18F-BR-351, suggesting that their expression after stroke are subsequent
or independent phenomena [220]. While TSPO is known to be an early biomarker in the
neuroinflammation cascade, another longitudinal investigation, using 18F-FSPG and 18F-DPA-714,
in the cerebral ischemia model displayed an earlier expression of the cystine/glutamate antiporter
(system xc-), involved in glutamatergic excitotoxicity, compared to TSPO imaging, evidencing its novel
role on inflammation after cerebral ischemia [221]. 18F-FSPG, a system xc- PET tracer, combined with
11C-PK11195 has also been used during the course of experimental autoimmune encephalomyelitis
(EAE) induction in rats. In this MS model, 18F-FSPG showed on the one hand a significant increase of
system xc-function in the lumbar section of the spinal cord at 14 days but, on the other hand, showed a
significant increase of microglial/macrophage activation in the spinal cord and cerebellum two weeks
after EAE induction. These dissimilar binding profiles between both PET tracers might be due to the
existence of different microglial/macrophage populations throughout the CNS following MS [222].
In the same way, to assess COX implication during the neurodegenerative process in AD, COX-1 and
TSPO PET co-imaging provided details of the time course in the inflammatory process in a rodent
model of neuroinflammation (induced by intrastriatal injection of lipopolysaccharide or quinolinic
acid). High accumulation of COX-1 tracer (11C-ketoprofen methyl ester) was observed in the early
phase, matching with the time course of microglial activation and macrophages, whereas the high
accumulation of 11C-PK11195 started slowly and lasted until at least 14 days afterward, corresponding
to changes in both the activation of microglia/macrophages and astrocytes [223].
Thus, upregulated biomarkers in reactive glial cells complementary to TSPO are expected in
order to fulfill the current clinician’s expectancies regarding the microglial role in neurodegenerative
diseases and associated potential novel therapeutic approaches.
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4.1.2. Dopaminergic PET Imaging
Dopaminergic neurotransmission is a key player in various brain functions, including behavior
and motor functions, and is involved in the pathogenesis of psychiatric (e.g., SCZ, depression)
and neurological disorders (e.g., PD, parkinsonian syndromes) [224]. Movement disorders are
strongly linked with dopaminergic impairment of the striato-pallido-thalamic-cortical axis in which
the striatum receives afferent projections from cortical glutamatergic and nigral dopaminergic
neurons [225]. Molecular imaging of dopaminergic presynaptic integrity (e.g., DAT with 11C-CFT or
18F-FE-PE2I), dopamine synthesis and turnover (e.g., 18F-DOPA) and postsynaptic dopamine receptors
(18F-Fallypride) are used to evaluate this dopaminergic pathway in various CNS conditions [224].
Experimental models of PD suggest that microglial activation may lead to dopaminergic neuronal loss
though iNOS-dependent oxidative stress [226]. Three clinical studies have been performed to assess
this association between microglial activation and dopamine terminal loss in PD [49,51,62]. Concerning
PD patients under antiparkinsonian medication, association analysis revealed that microglial activation
did not correlate significantly with either putaminal 18F-DOPA signal [65] or nigrostriatal DAT levels,
objectified by 18F-FE-PE2I binding [62]. Nevertheless, the mechanism of action of antiparkinsonian
drugs is based on the enhancement of dopaminergic transmission in the brain, therefore in this situation
PET imaging of the dopaminergic system is de facto biased, as previously demonstrated [227,228].
The one study conducted on ten drug-naive patients with PD (rated at stage 1 to 2 on the Hoehn
and Yahr scale) brought out the fact that 11C-PK11195 binding in the midbrain significantly and
negatively correlated with those for 11C-CFT in the dorsal putamen, a region known to engage
in motor execution [49]. Moreover, this microglial activation correlated positively with the motor
severity (UPDRS assessment) [49], suggesting a causal deleterious relationship between microglial
activation and nigrostriatal pathway impairment, both clinically (UPDRS) and biochemically (central
hypodopaminergism). However, this association does not elucidate the sequence of events. Indeed,
dopaminergic neuronal loss is accompanied by the release of endogenous constituents known as
damage-associated molecular patterns (DAMPs), which are able to activate microglial cells [229].
4.1.3. Abnormal Protein Aggregates PET Imaging
Amyloid deposition, tangle formation, activated microglia and neuronal dysfunction are
pathological processes involved in AD. However, the relative role of these processes in driving disease
progression is still unclear. As stated above, microglia PET imaging in AD provides heterogeneous
findings, hence the association analysis between fibrillar β amyloid, objectified by 11C-PIB binding,
and microglial activation could (i) investigate longitudinal changes of microglial activation and
amyloid; and (ii) assess the temporospatial relationship between these processes in AD. Indeed,
a positive correlation was found in most of the cortical regions between amyloid burden and microglial
activation [103,110,217]. Longitudinal study revealed that this correlation was less pronounced at
follow-up, and the location of the correlated regions presented a dynamic change [103], suggesting
that microglial activation is not static and its progression during AD may fit with the model of
Calsolaro et al. [99]. Furthermore, the positive correlation between amyloid load and microglial
activation is stronger in AD patients than in MCI patients, suggesting that microglial activation could
be driven by the presence of amyloid deposition [103] while other studies challenged these findings in
MCI patients [111,115]. Likewise, a positive correlation was seen in the parietal lobe and the anterior
cingulate cortex in PDD patients [125]. This combined approach of amyloid and microglial imaging
is nevertheless submitted to debate by some studies pointing out no correlation [101,105,109,111] or
negative association with amyloid deposits in the posterior cingulate cortex in AD patients [106].
On the same model as the amyloid/microglia imaging, with the emergence of new NFTs PET
tracers, the combined use of tau and microglial imaging should also contribute to the pattern of
distribution of the increased tau deposition and widespread microglial activation in AD subjects. Not
only because post mortem and initial tau imaging studies indicate that the amount of tau deposition
and their topographical distribution in the brain might be more relevant, and more tightly associated
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with neurodegeneration and cognitive decline than β amyloid deposition [114], but also because in
studies of tau model mice using 18F-FEDAA1106 or 11C-Ac-5216, microglial TSPO expression was
linked to neurotoxic tau pathology. Nevertheless, to our knowledge, no combined use of tau and
microglial imaging study has been performed to date.
Furthermore, recent studies suggest that neuroinflammation and α-synuclein disorders
are interconnected processes which promote each other and perpetuate neurotoxicity. This
interaction leads to distinct microglial polarization states and drives the chronic progression of
neurodegeneration [230,231]. Thus, it seems appropriate to combine neuroinflammation/α-synuclein
imaging, for which efficient radiopharmaceutical are currently strongly expected.
4.1.4. PET Tracer in MS
Microglia PET imaging (11C-PK11195) has been used in combination with 11C-methionine for the
differential diagnostics between tumefactive MS lesion and low-grade glioma in a case report [231].
Beside this diagnostic potential of TSPO PET imaging in MS as previously described, the hopeful results
of myelin PET tracers in animal studies such as 11C-CIC or 11C-MeDAS (for review, see Faria et al. [185])
lead us to believe that a multiplexed approach with these radiotracers could allow us to understand
the relationship between the demyelination/remyelination process and microglial activation in MS.
4.1.5. Cerebral Metabolic State Imaging: 18F-FDG
Cerebral glucose metabolic rate (rCMRGlc) measured by 18F-fluorodeoxyglucose (18F-FDG) PET is
currently the most accurate in vivo method for the investigation of regional human brain metabolism,
and is suggested to be to be an indirect measure of synaptic function [132]. Thus, changes in neuronal
activity induced by neurodegenerative diseases are reflected in an alteration in glucose metabolism.
A significant negative correlation between microglial activation and glucose metabolism
was present in the hippocampus [125,132], medial temporal cortex [125] in AD patients, in the
temporoparietal and occipital cortex [125] and hippocampus [132] in PDD patients, and in the
hippocampus in MCI patients [125] . This inverse correlation implies the direct damaging effect by the
activated microglia on neuronal loss in AD and PDD, objectified by the glucose metabolism decrease.
In addition, Fan and colleagues have used three combined molecular imaging radiopharmaceuticals
(11C-PIB, 11C-PK11195 and 18F-FDG) to show a correlation between amyloid load, levels of microglial
activation, and reduced glucose metabolism in AD and, to a lesser extent, in MCI and PDD subjects;
furthermore, the correlation between amyloid load and glucose metabolism was more extensive at
follow-up and was consistently associated with cognitive decline in AD patients, suggesting that, once
synaptic dysfunction occurs, the disease is active and progressive [85].
4.2. Multimodal Approaches
4.2.1. Imaging Modalities Other Than PET
In order to investigate CNS disorders by a broader approach combining concomitantly
complementary pathophysiological aspects, the use of TSPO PET in a multimodal neuroimaging
strategy has increased significantly in recent years. In this framework, MRI and its different subtypes
(i.e., structural, diffusion and functional MRI) are among the most democratized approaches, in
combination with TSPO PET imaging.
Brain atrophy assessed in structural MRI has been found in various CNS disorders [232]. This
is especially true in AD, where hippocampal atrophy correlates with clinical decline and assumes
the status of both the diagnostic and imaging biomarker of AD progression [233]. This approach
was used to assess the relationship between microglial activation and neurodegenerative process
in AD [101,124], PDD [132], SCZ [177] and MS [200,205,213,218]. Indeed, the amount of activated
microglia in the whole cortex, medial temporal lobe and hippocampus was inversely correlated with
hippocampal volume and 18F-FDG hippocampal uptake in AD and PDD patients [132]. In front of
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this spatial agreement between microglial activation in the cortical projections from the hippocampus
and hippocampal atrophy, the authors assumed that microglial cells in a reactive state might be one
of the effectors of neurodegeneration [132]. The same association between TSPO density increase
and cerebral volume decrease reached significance in various cortical regions such as the inferior
parietal lobule, precuneus, superior temporal cortex and especially in the prefrontal cortex [101],
in which interconnection with the thalamus and hippocampus [233] are strongly linked to episodic
memory impairment in AD patients [234]. On the contrary in BD-I patients, association analysis
between 11C-PK11195 binding potential and hippocampal volume failed to exhibit a significant
relationship [170]. Quantitative magnetization transfer imaging (qMTI), an advanced structural MRI
technique providing information about in vivo tissue integrity, is able to detect inflammation-related
changes in brain microstructures [235]. Furthermore, qMTI in MS patients has shed light on the
pattern of tissue structural abnormalities in NAWM being greatest near the ventricles [236]. In a
way to characterize the temporal/sequential/spatial relationship between microglial activation and
anatomically objective brain lesions, a coupling TSPO PET/qMTI could be a promising approach,
especially in MS.
Diffusion-weighted imaging, reflecting (ab)normal tissue diffusivity (measured by apparent
diffusion coefficient (ADC)), has been used in combination with 11C-PK11195 in PD, MSA and PSP
patients [61]. Although the small sample size limits the scope of study’s conclusions about the impact
of microglial activation on tissue damage, a positive correlation between microglial activation and
ADC was found in the pons of atypical parkinsonism patients. Given the fact that ADC indirectly
reflects cellularity, this association suggests a causal relationship between microglial activation/TSPO
overexpression and gliosis.
fMRI is a technique that uses blood-oxygen-level-dependent (BOLD) contrast to detect changes
in brain hemodynamics. Hippocampal functional connectivities to the subguenal and prefrontal
and parietal regions correlated with the beck depression inventory scores and 18F-PBR111 DVR in
MS patients. This correlation analysis between hippocampal 18F-PBR111 binding and functional
connectivity, assessed by fRMI, lead authors to hypothesize that microglial activation is involved in
MDE pathophysiology in MS patients [218]. Besides “conventional fMRI”, innovative techniques like
GluCEST (Glutamate chemical exchange saturation transfer) appear to be hopeful tools to assess and
understand neuroinflammation [237], and may be even more useful in a multiplexed approach with
microglia PET imaging.
Beyond the interest of coupling MRI techniques with TSPO PET modality, recent advances in
imaging of activated microglia have been shown promising results. Indeed, 2D optical imaging
spectroscopy [238] or optical projection tomography applied to a 3D spatial assessment of the
development of neuroinflammation [239] provided positive outcomes in rodent models.
4.2.2. Biology
The understanding of the microglial activation status in neurodegenerative disorders could be
reached by coupling microglia PET imaging to several biological techniques including metabolomics,
transcriptomics, magnetic resonance spectroscopy (MRS) and measurement of central and/or
peripheral pro-inflammatory components. Among these, 1H MRS in BD-I patients provided surprising
results. Whereas no relationship was found between phosphocholine + glycerophosphocholine
concentrations, cellular turnover biomarkers and microglial activation; N-acetylaspartate +
N-acetyl-aspartyl-glutamate concentrations, representing loss of neuronal integrity when levels
decreased, were positively associated with 11C-PK11195 binding in the left hippocampus [170].
These findings challenged the neuroinflammation theory of psychiatric disorders in which activating
microglia have a negative effect on neuronal survival [240].
In MS patients with a higher inflammatory load, the concentration of myoinositol, a metabolite
which has been proposed as a glial and especially as an astrocyte marker [241], was correlated with
11C-PBR28 DVR in WM lesions, suggesting the joint activation of astrocytes and microglia in MS [211].
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The association between inflammatory biomarkers (cytokine levels [89,168], or proteins
carbonylation [54] and TSPO PET imaging in neurodegenerative disorders was also the subject
of several studies. Early stage dementia with Lewy bodies (DLB) and PD patients exhibited
significantly greater levels of total carbonylated proteins in cerebrospinal fluid (CSF) than healthy
controls, suggesting that relative aspecific oxidative modifications occurred in both neurodegenerative
disorders [54]. The lack of correlation between central inflammation measured by 18F-FEPPA VT and
levels of several pro-inflammatory cytokines such as IL-1β , IL-6 and TNF-α supports the idea that
microglial activation can occur in MDE even when peripheral inflammation is absent [168]. In patients
with recent onset of SCZ, the absence of this association has also been found between 11C-DPA713 VT
and both plasma and cerebrospinal fluid IL-6 levels [176].
5. TSPO PET Imaging Potential Added Value in the Clinical Practice
As discussed above, TSPO PET imaging has been used in a large number of studies concerning
neurodegenerative diseases over the past 20 years. However, such a major investment has not
yet resulted in an expected impact for clinical practice. In AD or SCZ, for instance, our present
analysis came to conflicting results, which are moreover based on small numbers (<100) of patients.
The overall trend that could be drawn from these studies would suggest that early microglial activation
could represent a beneficial response, whereas chronic exposure would induce detrimental effects by
promoting neuronal death, thus contributing to the progression of the disease.
A comparison between PET radioligands’ development, targeting TSPO and β-amyloid
(Aβ) plaques, respectively, illustrates this assessment: while the first clinical uses of these
radiopharmaceuticals were approximately contemporaneous, those of 11C-PK1195 being even much
earlier than those of 11C-PiB and 18F-FDDNP (two of the first developed Aβ tracers) [242,243], several
Aβ-radiopharmaceuticals are nowadays routinely used to assess amyloid-β burden in a clinical setting.
Aβ-PET represents a major advance in the evaluation of patients with cognitive impairment when
AD is a possible cause, and affects the diagnosis and the resulting treatment recommendations [243].
TSPO radiopharmaceuticals (18F-DPA714, 18F-FEPPA, 18F-PBR06, or 18F-GE180 being among the most
promising ones), remain at the same time dedicated to specialized PET centers and restricted to
research applications.
The current state of knowledge, which clearly identifies the neuroinflammation process as a
constitutive part of the pathophysiology of neurodegenerative diseases, might give a new impetus for
TSPO PET imaging, especially for the noninvasive and longitudinal evaluation of anti-inflammatory
therapies for these diseases. For instance, Ratchford et al. recently reported a longitudinal TSPO PET
study evaluating microglial activation in MS. One year treatment with glatiramer acetate reduced
TSPO binding significantly in both cortical gray matter and cerebral white matter, when compared
with cerebellum [204]. This promising approach gives excellent comparative data for longitudinal
TSPO PET studies evaluating therapeutics in progressive diseases. Nevertheless, several drawbacks
limit the ability of TSPO as a PET imaging molecular target in routine clinical practice, such as the
identified polymorphism affecting the binding affinity properties of most of TSPO ligands and the
TSPO multicellular expression, among others. Thus, we mentioned above the interest of TSPO imaging
combined with further PET targets, but the dissimilar binding profile observed and its correlation with
neuroinflammation cellular dynamics remains a major issue for understanding the pathophysiological
and clinical relevance of what we are imaging.
6. Conclusions
TSPO PET tracers were the most widely used and allowed us to better characterize
microglia-related neuroinflammation in terms of intensity, localization and static/dynamic feature of
microglial activation in various neurodegenerative troubles. Recent studies challenged the paradigm
that activated microglia are detrimentally involved in neurodegenerative process. Indeed, microglia
seem to play a role in CNS disorders with a relative dichromatic status that occurs in a time-dependent
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fashion. With the benefit of hindsight over 25 years, TSPO PET imaging showed several limitations in
relation to the multicellular expression of the target or its similar expression, whatever the microglia
polarization state. Thus, new PET biomarkers reflecting some specific functions of activated microglia
(e.g., polarization, microglial oxidative stress-related) conjugated with a multiplex strategy combining
several modalities (imaging, biology) may solve clinicians’ concerns about characterizing the role of
activated microglia over the progression of CNS disorders.
Finally, the usefulness of TSPO PET imaging as a major research tool has appeared inescapable
over years. Indeed, it has allowed for better understanding of the neuroinflammation process in
CNS disorders, and the multiplex approach, either unimodal or multimodal, would certainly broaden
the knowledge of this issue. Nowadays, however, the main challenge remains to identify the scope
of TSPO PET imaging for a transfer in routine clinical use whether as a diagnostic, prognostic or
therapeutic effects assessment tool.
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